- ProMIS Neurosciences’ (PMN) PMN310 antibody demonstrates significant cognitive benefits in a mouse model of Alzheimer’s disease
- The APP/L mouse is a “transgenic” model of AD in which human amyloid-beta oligomers lead to cognitive deficits
- This positive result builds on earlier in vivo data for PMN310
- ProMIS Neurosciences, Inc. is a development stage biotechnology company focused on discovering and developing antibody therapeutics
- ProMIS Neurosciences’ (PMN) is up 3.85 per cent, trading at C$0.14 at 11:32 am EST
ProMIS Neurosciences’ (PMN) PMN310, showed a significant cognitive benefit in a widely recognized animal model of AD.
The APP/L mouse is a “transgenic” model of AD in which human amyloid-beta oligomers lead to cognitive deficits.
In this model, treatment with PMN310 which selectively targets toxic oligomers of amyloid-beta preserved memory using the water maze readout, to the extent that the PMN310 treated mice were indistinguishable from “non-transgenic” control mice.
“This model closely aligns with the most current understanding of the biology of Alzheimer’s disease, that small clumps of misfolded amyloid-beta are the most pathogenic species”, stated Dr. Neil Cashman, ProMIS Chief Scientific Officer.
“In our opinion, studies in transgenic mouse models that focus on plaque removal or monomer depletion are not representative of human disease,” added Cashman.
This positive result builds on earlier in vivo data for PMN310.
We have previously published on the protective activity of PMN310 in a novel object recognition model where toxic oligomers of amyloid-beta are injected into the brain of mice to create a memory deficit.
In this model, co-injection of PMN310 prevented the loss of memory caused by toxic oligomers.
Commenting on today’s announcement, ProMIS Chairman and CEO, Eugene Williams stated: “The observed positive outcome with systemic administration of PMN310 is very encouraging, as PMN310 is on track for an IND filing by year-end in its initial formulation for intravenous/infusion delivery.”
ProMIS Neurosciences, Inc. is a development-stage biotechnology company focused on discovering and developing antibody therapeutics selectively targeting toxic misfolded oligomers implicated in the development and progression of neurodegenerative diseases, in particular Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinson’s disease (PD).
Its proprietary target discovery engine is based on the use of two complementary computational modelling techniques.
ProMIS Neurosciences’ (PMN) is up 3.85 per cent, trading at C$0.14 at 11:32 am EST.